EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal Protects against mutant strainsPromotes a long term memory responseNo side effects in healthy volunteersVaccine stored and transported at room temperature with long shelf lifeSeeking...

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both...

Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response Works against mutant strains including DeltaNo need for refrigeration during transport and storage No added stabilisers or chemicals Safety and immune response clinical trial recruiting now in...